Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus
Dan Ollendorf, MPH
Advertisement
Articles by Dan Ollendorf, MPH
Advertisement
Latest Updated Articles
- Impact of Uracil/Tegafur Plus Oral Calcium Folinate on Resource Utilization
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
4
3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer
5
